SPS
CCCC icon

Susquehanna Portfolio Strategies’s C4 Therapeutics CCCC Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
335,079
+74,800
+29% +$256K 0.02% 479
2026
Q1 		$685K Sell
260,279
-11,774
-4% -$27.7K 0.01% 703
2025
Q4 		$520K Hold
272,053
– – 0.01% 777
2025
Q3 		$604K Buy
272,053
+145,153
+114% +$348K 0.01% 785
2025
Q2 		$181K Buy
+126,900
New +$185K ﹤0.01% 803
2024
Q2 		– Sell
-91,127
Closed -$745K – 558
2024
Q1 		$745K Hold
91,127
– – 0.02% 515
2023
Q4 		$515K Buy
+91,127
New +$208K 0.01% 759

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Susquehanna Portfolio Strategies's CCCC Position: Q2 2026 in Review

Susquehanna Portfolio Strategies increased its C4 Therapeutics (CCCC) stake by 29% in Q2 2026, buying an estimated $256K and bringing the position to 335,079 shares worth $1.56M. The position accounts for 0.02% of the portfolio, ranked #479.

Susquehanna Portfolio Strategies first reported a position in CCCC in Q4 2023 and has held it in 7 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Susquehanna Portfolio Strategies held 335,079 shares of C4 Therapeutics worth $1.56M as of Q2 2026.
  • Susquehanna Portfolio Strategies bought 74,800 C4 Therapeutics shares in Q2 2026, an estimated $256K.
  • C4 Therapeutics made up 0.02% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #479 holding.
  • Susquehanna Portfolio Strategies first reported a position in C4 Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.